Andrade FRT, Buchborn T, Thalheimer G, Meinhardt M, Joca S, de Almeida RMM. Exploring the Effects of Psilocybin on Depression and the Mediating Role of the 5-HT2A Receptor: A Systematic Review. Acta Neuropsychiatr. 2025 Sep 3. [Epub ahead of print] :1-53.
De Prisco M, Tapoi C, Oliva V, Strumila R, Takami C, Girone N, Macellaro M, de Salles Andrade JB, Schmitz C, Vieta E, Fico G. Clinical impact of obsessive-compulsive disorder comorbidity in bipolar disorder: a systematic review and meta-analysis. Eur Psychiatry. 2025 Aug 26. [Epub ahead of print] :1-34.
Gebest M, Weiss C, Cho CG, Hausner L, Frölich L, Förster A, Santhanam N, Fontana J, Groden C, Wenz H, Maros ME. Longitudinal automated brain volumetry versus expert visual assessment of atrophy progression on MRI: an exploratory study. Sci Rep. 2025 15(1):14968.
Gründer G, Bauer M. [Between efficacy and criticism: antidepressants in discourse]. Nervenarzt. 2025 96(2):117-118.
Gründer G, Bauknecht P, Schell S, Leopold K, Paulzen M, Leucht S. Identification and Rating of Treatment Goals in Schizophrenia: Delphi Process and Concordance Survey in Matched Physician-Patient Pairs. Patient Prefer Adherence. 2025 19:1029-1046.
Gründer G, Mertens L, Jungaberle A, Jungaberle H, Spangemacher M. Compassionate use of psilocybin for treatment-resistant depression in Germany. Lancet Psychiatry. 2025 Sep 18. [Epub ahead of print]
Gründer G, Mertens L, Spangemacher M, Schmitz C. [Can antidepressants negatively alter the long-term course of depressive disorders?]. Nervenarzt. 2025 96(2):146-152. Epub 2025 Feb 24.
Meinhardt M, Skorodumov I, Jeanblanc J, Benvenuti F, Hilal FF, Domi E, André C, Bodeau S, Jeanblanc V, Domanegg K, Ciccocioppo R, Naassila M, Spanagel R. A new module in the drug development process: preclinical multi-center randomized controlled trial of R-ketamine on alcohol relapse. Neuropsychopharmacology. 2025 50(6):886-894. Epub 2025 Feb 28.
Mlynek E, Tan X, Lammertz SE, Schaffrath S, Gründer G, Schneider F, Frodl T, Mathiak K, Gaebler AJ. Disturbed Functional Connectivity Between Anterior Default Mode and Sensory Processing Regions Is Linked to Peripheral Inflammatory Markers and Psychopathology in Schizophrenia. Schizophr Bull. 2025 Apr 23. [Epub ahead of print] 15:153.
Schmitz CN, Hart XM, Spangemacher M, Roth JL, Lazarevic I, Oberthür G, Büsing KA, Becker R, Cumming P, Gründer G. Neurovascular coupling of striatal dopamine D receptor availability and perfusion using simultaneous PET/MR in humans. Neurosci Appl. 2025 3:104094.
Spangemacher M, Reinwald J, Adolphi H, Kärtner L, Mertens LJ, Schmitz CN, Gründer G. [Mechanisms of action of antidepressive pharmacotherapy: brain and mind-body and environment]. Nervenarzt. 2025 96(2):119-127. Epub 2025 Jan 16.
Wolff M, Rutrecht H, Gründer G, Jungaberle A, Jungaberle H. Key competencies for psychedelic treatment in real-world mental health care settings. Gen Hosp Psychiatry. 2025 Sep 16. [Epub ahead of print] 97:11-24.
Yaden DB, Graziosi M, Owen AM, Agin-Liebes G, Aaronson ST, Allen KE, Barrett FS, Bogenschutz MP, Carhart-Harris R, Ching THW, Cosimano MP, Danforth A, Davis AK, Garcia-Romeu A, Griffiths R, Grob CS, Gründer G, Gukasyan N, Heinzerling KG, Hendricks PS, Holze F, Horton DM, Johnson MW, Kelmendi B, Knatz Peck S, Koslowski M, Liechti ME, Mertens LJ, Moreno FA, Nayak SM, Nicholas CR, Preller KH, Rieser NM, Ross S, Sergi K, Sloshower J, Smigielski L, Stenbæk DS, Vollenweider FX, Weiss B, Wolff M, Yaden ME. A Field-Wide Review and Analysis of Study Materials Used in Psilocybin Trials: Assessment of Two Decades of Research. Psychedelic Med (New Rochelle). 2025 3(1):1-18.